Late in 2005 the Food and Drug Administration approved Celgene’s Revlimid. The drug brought in $321 million in sales its first full year on the market. A decade later it collected a cool $6.97 billion (more than 60% of the biotech’s 2016 revenues), and sales are expected to cross the $8 billion mark this year. Celgene has ridden Revlimid’s success and approvals for various diseases to a 270% gain in market value in 10 years. Now analysts are bullish on the company’s experimental treatments for multiple sclerosis, ulcerative colitis, and Crohn’s disease.
Mark J. Alles
|Revenues ($M) (Past 12 Months)||$12,191|
|Profits ($M) (Past 12 Months)||$2,602|
|Market Value as of Oct. 9, 2017 ($M)||$108,958|